Video

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes.

Most available therapies in relapsed/refractory peripheral T-cell lymphoma (PTCL) elicit response rates around 30%, which represents a major unmet need in the space, Jagadeesh says.

Notably, duvelisib (Copiktra) has demonstrated slightly higher historical response rates in patients with relapsed/refractory PTCL, Jagadeesh says. Moreover, brentuximab vedotin (Adcetris) has shown encouraging response rates in patients with anaplastic large cell lymphoma.

 Despite this, few treatment options are available for patients with rare lymphoma subtypes because it is difficult to enroll them onto clinical trials, Jagadeesh explains. This can be true even if the patient is eligible for enrollment.

 As such, additional data are needed to draw meaningful conclusions regarding the efficacy of novel therapies in this space, Jagadeesh concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity